Lista de obras - Edward Marc John Vital - Dominio Público Uruguay

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

artículo científico publicado en 2019

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

scientific article published on 05 August 2019

A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. ⬇️

artículo científico publicado en 2018

Abatacept in the treatment of rheumatoid arthritis

artículo científico publicado en 2008

Abatacept in the treatment of rheumatoid arthritis

artículo científico publicado en 2006

An immunological biomarker to predict MTX response in early RA.

artículo científico publicado en 2013

Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort

scientific article published on 25 April 2019

B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus

scientific article published on 05 December 2019

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. ⬇️

artículo científico

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress ⬇️

artículo científico publicado el 1 de agosto de 2013

Biologics in systemic lupus erythematosus: current options and future perspectives

artículo científico publicado en 2014

Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.

artículo científico publicado en 2014

Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab.

artículo científico publicado en 2017

Co-stimulatory blockade as therapy for rheumatoid arthritis

artículo científico publicado en 2005

Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus ⬇️

artículo científico publicado el 6 de abril de 2012

Costimulation blockade in rheumatic diseases: where we are?

artículo científico publicado en 2009

Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise ⬇️

artículo científico publicado en 2017

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre ⬇️

artículo científico publicado en 2017

Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis

artículo científico publicado en 2020

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

artículo científico publicado en 2011

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis ⬇️

artículo científico publicado en 2017

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity

artículo científico publicado en 2020

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

artículo científico publicado en 2008

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism ⬇️

artículo científico publicado en 2015

Musculoskeletal manifestations of systemic lupus erythmatosus

artículo científico publicado en 2017

Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. ⬇️

scientific article published on 29 June 2016

Patients' experiences of lupus-related foot problems: a qualitative investigation

artículo científico publicado en 2017

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

artículo científico publicado en 2020

Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic? ⬇️

artículo científico publicado en 2014

Plasmacytoid dendritic cells are functionally exhausted while non-haematopoietic sources of type I interferon dominate human autoimmunity: Supplemental Figures and Tables

scholarly article published 20 December 2018

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature

scientific article published on 14 July 2019

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases

artículo científico publicado en 2019

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus ⬇️

artículo científico publicado en 2017

Publisher Correction: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features ⬇️

artículo científico publicado en 2018

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

artículo científico publicado en 2011

Response to: 'Which B-cell subset should we target in lupus?' by Ferraccioli and Houssiau

artículo científico publicado en 2014

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus ⬇️

scientific article published on 03 January 2019

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? ⬇️

artículo científico publicado en 2017

Rituximab biosimilars

artículo científico publicado en 2013

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis

artículo científico publicado en 2006

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis ⬇️

artículo científico publicado en 2016

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation

artículo científico publicado en 2021

The development of targeted therapies in rheumatoid arthritis

artículo científico publicado en 2008

The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus

artículo científico publicado en 2017

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

artículo científico publicado en 2017

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

artículo científico publicado en 2017

The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey.

artículo científico publicado en 2016

The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review ⬇️

artículo científico publicado en 2016

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus

scientific article published on 14 September 2019

Determinants of response to B cell depletion in rheumatic diseases

tesis doctoral

Lista de obras de Edward Marc John Vital

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. ⬇️

Abatacept in the treatment of rheumatoid arthritis

Abatacept in the treatment of rheumatoid arthritis

An immunological biomarker to predict MTX response in early RA.

Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort

B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. ⬇️

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress ⬇️

Biologics in systemic lupus erythematosus: current options and future perspectives

Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.

Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab.

Co-stimulatory blockade as therapy for rheumatoid arthritis

Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus ⬇️

Costimulation blockade in rheumatic diseases: where we are?

Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise ⬇️

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre ⬇️

Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis ⬇️

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism ⬇️

Musculoskeletal manifestations of systemic lupus erythmatosus

Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. ⬇️

Patients' experiences of lupus-related foot problems: a qualitative investigation

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic? ⬇️

Plasmacytoid dendritic cells are functionally exhausted while non-haematopoietic sources of type I interferon dominate human autoimmunity: Supplemental Figures and Tables

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus ⬇️

Publisher Correction: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features ⬇️

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

Response to: 'Which B-cell subset should we target in lupus?' by Ferraccioli and Houssiau

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus ⬇️

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? ⬇️

Rituximab biosimilars

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis ⬇️

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation

The development of targeted therapies in rheumatoid arthritis

The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey.

The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review ⬇️

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus

Determinants of response to B cell depletion in rheumatic diseases